CANTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that
management will present at the following investor conferences in September:
- The 19th Annual Rodman & Renshaw Global Investment Conference on Monday, September 11th at 12:05 p.m.
ET at the Lotte New York Palace Hotel
- The Cantor Fitzgerald Global Healthcare Conference on Monday, September 25th at 4:45 p.m. ET at the
InterContinental New York Barclay Hotel
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary
DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is
designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alex Dasalla [email protected]
